
Opinion|Videos|January 3, 2025
Exploring ADC/Antibody Combination Therapies in Development for R/R FL
Author(s)Juan Pablo Alderuccio, MD
A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Next, provide context for combination loncastuximab plus+ rituximab in R/R FL.
- How can novel combinations that include antibody-drug conjugates (ADCs) impact the landscape?
- Introduce loncastuximab: target, MOA. What was the rationale for testing loncastuximab plus+ rituximab in R/R FL?
- Patients with FL patients from pPhase 1 loncastuximab in R/R B-NHL
- What additional preliminary evidence supports the combination in this setting?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
4
FDA Grants Orphan Drug Designation to IFx-2.0 for Advanced Melanoma
5



















